Company ProfilePremium

GCH Technology Co., Ltd.

Company Profile Analysis

呈和科技股份有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
GCH Technology Co., Ltd. - Company showcase

Year Founded & Workforce

2002

255 Employees

GCH Technology Co., Ltd. logo

GCH Technology Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

GCH Technology Co., Ltd. Overview

Data conflict on business description. Two aggregator profiles (financialfilings.com and disfold.com) describe the company as a power-semiconductor or semiconductor-materials maker. That description is incorrect. Every primary filing shows a specialty polymer-additives company that is now expanding into electronic resins for copper-clad laminates (CCL).

GCH Technology is China's leading domestic producer of polymer nucleating agents. These are additives that raise the crystallinity, clarity, stiffness or toughness of polypropylene and polyethylene. The company is also a leading Chinese supplier of synthetic hydrotalcite, used as a lead-free PVC heat stabiliser and as an acid scavenger in polyolefin production. Its core franchise sits upstream of high-performance resin production at Sinopec, PetroChina, CNOOC-Shell, Wanhua, Hengli and other petrochemical majors. That franchise earns gross margins above 55% on nucleating agents, far above Chinese additive peers. The investment case rests on import substitution against Milliken, Adeka and Kyowa Chemical. Overseas sales are accelerating (+52.6% in FY2025), helped by the acquisition of France-based Palmarole Trading. Since January 2026 the company has been repositioning toward electronic-grade PPO resin and halogen-free flame retardants for high-frequency/high-speed CCL used in AI servers and communications. Equity markets have re-rated the shares more than twofold on this story, ahead of any material revenue contribution.


Company's own description (FY2023 and FY2025 annual reports, paraphrased)

The company describes itself as a high-tech manufacturer of environmentally friendly, safe, high-performance specialty polymer additives. Its products sit at the upstream core of high-performance resin and modified-plastics manufacturing. They improve the optical and mechanical properties and stability of commodity resins. The resulting resins serve food-contact packaging, medical devices, pharmaceutical packaging, infant products, automotive parts, appliances, building materials and agricultural facilities.

The company holds several state designations:

  • MIIT national "Specialised, Refined, Distinctive and Innovative" (专精特新) "little giant"

  • National Manufacturing Single-Item Champion, for nucleating agents

  • National Green Factory

It also says it was the first Chinese company to obtain US FDA food-contact-substance clearance for its products. It holds Novolen (2017) and Unipol (2019) polypropylene process-licensor qualifications, which put it on major petrochemical approved-vendor lists.

Product families (self-produced)

  1. Nucleating agents (成核剂): clarifying (transparent), stiffening, and β-crystal toughening grades, sold as single additives and as nucleator-containing compound blends.

  2. Synthetic hydrotalcite (合成水滑石): general-purpose, high-transparency ternary (Mg-Al-Zn) and flame-retardant grades, used as PVC heat stabiliser and polyolefin halogen/acid scavenger.

  3. Antioxidants (抗氧剂): specialty hindered-phenol grades, added via the 2023 acquisition of Keao Chemical (科澳化学).

  4. Compound additives (复合助剂): dust-free one-pack blends. These include "NDO" compounds, which contain none of GCH's own nucleators or hydrotalcite.

  5. Electronic materials (since Jan 2026): electronic-grade PPO (polyphenylene ether) resin and high-frequency/high-speed flame retardants for CCL. These came via the 80.89% acquisition of Guangdong Juxun New Materials (聚讯新材料).

Trading business

The company also runs a trading business, split into two models:

Proprietary trading (自主贸易): booked gross, with inventory and credit risk carried by the company.

Agency trading (代理贸易): booked net, with no title to goods.

Traded products include general-purpose antioxidants, polypropylene, catalysts, slip/anti-block agents and other additives. Five group entities carry this out: the parent, Shanghai Chenghe International Trade, Guangzhou Chenghe Plastics New Materials, Hong Kong Chenghe Technology and Tianjin Xindafeng Import & Export (Inquiry Reply).

Business and revenue model

DimensionCharacterisation
Revenue modelEssentially 100% product sales. FY2025: self-produced additives CNY 895.8M (91.7%) and trading CNY 81.4M (8.3%). No subscription or licensing revenue. A small amount of technical-service revenue is disclosed for one customer (Inquiry Reply).
Sales modelDirect sales to two customer types. End customers (petrochemical majors, resin compounders, additive blenders) took CNY 651.3M in FY2025. Traders on a buy-out basis took CNY 244.5M. Consignment ("zero-inventory") arrangements apply for some petrochemical customers.
Production modelMake-to-order with about one month of safety stock. Production lines and core equipment are designed in-house.
ProcurementAromatic aldehydes, aromatic carboxylic acids, antioxidants and other intermediates, bought "per production plan".
Value-chain positionUpstream specialty-additive supplier to polyolefin and PVC producers, and to compounders for packaging, automotive, appliance and medical end-uses. New electronic-materials step: resin and flame-retardant supplier to CCL makers, which supply PCB makers serving AI servers and telecoms.
Customer concentrationTop-5 customers were 31.86% of revenue in FY2024 and 35.68% in FY2025. The largest customer, a petrochemical major (name withheld), accounted for 13.42% in FY2025 (Inquiry Reply).

Independent characterisation

GCH is best understood as a niche "molecule-plus-formulation" specialty chemicals company. Its moat is built from three things:

  • process know-how in sorbitol/phosphate-type clarifiers and hydrotalcite synthesis;

  • long qualification cycles with state-owned petrochemical majors;

  • a cost advantage over Milliken (US) and Japanese incumbents.

Margins are structurally high, about 45% gross and about 29% operating. Absolute scale remains small, below CNY 1bn of revenue. Capacity utilisation after the FY2024 Nansha expansion was only 55–57% in FY2025.

The 2026 pivot into CCL resins changes the risk profile. GCH moves from a slow-compounding import-substitution story into a capital-intensive, qualification-driven electronic-materials race. It does so against Shengquan, Dongcai, SABIC, Mitsubishi Gas Chemical and Asahi Kasei. The balance sheet carries a large "treasury" layer:

  • CNY 1.15bn of deposits, certificates and principal-protected notes at end-2025;

  • CNY 854M of short-term "debt", mostly discounted bank-acceptance bills not derecognised.

The fundamental net cash position is therefore stronger than headline gearing suggests, but it is opaque. The SSE explicitly queried it.

End-markets served

End-marketAdditive rolePrimary product
Food and beverage packaging (thin-wall injection, clear cups, microwaveable containers)Clarity, heat resistance, cycle timeClarifying and stiffening nucleators
Medical devices and pharmaceutical packaging (syringes, IV sets, blood bags)Clarity, safety, lead-freeNucleators, high-transparency hydrotalcite
Automotive (bumpers, door panels, thin-wall modified PP)Stiffness and toughness balanceStiffening and β-nucleators
Household appliancesStiffness, "plastic-for-steel" substitutionNucleators, compounds
PVC pipes, profiles, cables, artificial leatherLead-free heat stabilisationSynthetic hydrotalcite
Polyolefin polymerisation (petrochemical plants)Halogen/catalyst-residue scavengingHydrotalcite, NDO compounds
Agricultural filmIR absorption, heat retentionModified hydrotalcite
Nylon, rubber, fibres, wire and cableAnti-ageingSpecialty antioxidants
Battery separators (polyolefin microporous film)Pore structureNucleators
CCL / PCB for AI servers and telecoms (new)Low-Dk/Df resin, halogen-free flame retardancyElectronic-grade PPO, HF/HS flame retardants

Strategy

Stated strategy themes (FY2023–FY2025 ARs; investor communications; paraphrased)

  1. Import substitution in core additives. Expand domestic share of nucleators, where the import-substitution rate rose from 19% in 2017 to 28% in 2022, about 30% in 2023, and a projected 34% in 2025. Do the same in high-end hydrotalcite, where Kyowa Chemical, Sakai Chemical and Clariant still dominate.

  2. Internationalisation. Use cost-performance parity with Milliken to win global petrochemical accounts. The Palmarole acquisition is the channel platform for Europe and the Middle East.

  3. Platform upgrade into electronic materials. Move from "traditional resin-additive leader" to a "high-frequency/high-speed electronic-materials platform" (Guosen characterisation, consistent with management's Dongguan investment rationale).

  4. Green and low-carbon processes. CO2-route hydrotalcite, ISO 50001 certification, national green factory, and "zero-waste factory" status in Baiyun District.

  5. "Quality, Efficiency and Returns" action plan (提质增效重回报). An SSE-encouraged programme, with a 2026 plan and a half-year evaluation approved in August 2026.

Strategic initiatives in the last 24 months

DateInitiativeDetail / target
Apr–Jun 2025Attempted entry into sputtering targets (Yingri Technology)Indicative CNY 1.8bn valuation for 100%; at least 51% stake; terminated
Dec 2025Palmarole Trading SAS acquisitionUSD 9M for 100% plus a USD 15M capital increase; overseas regulatory approvals received Dec 2025 and Feb 2026
Dec 2025CETC Yizhihang 48%CNY 6.18M net; low-altitude economy and defence diversification
Jan 2026Juxun New Materials 80.89%Entry into electronic PPO and HF/HS flame retardants
Mar–May 20262026 Restricted Stock Incentive Plan6.72M shares (post-adjustment) at CNY 21.43 to 62 grantees.
Jun 2026Dongguan projectUp to CNY 1.3bn; PPO 2,500 t, flame retardant 2,500 t, high-end hydrotalcite 20,000 t; financed by raised funds, own funds and bank loans
Jun 2026UN Global Compact accessionFirst Communication on Progress due 31 Jul 2027
Jun–Aug 2026Management share purchaseCNY 30–60M range; CNY 59.92M executed
2,026R&D build-out28 projects in progress at June 2026: 4th-generation organophosphate nucleator, hydrotalcite for coatings, degradable and engineering plastics, electronic materials

Medium-term targets and guidance

Management has published no numerical medium-term revenue or margin targets. The only quantified forward data are capacity plans (Dongguan) and sell-side estimates (Guosen; Section 22).

The FY2025 capital-allocation choice signals priority for reinvestment over payout. The board chose a 4-for-10 capitalisation issue and no final cash dividend, explicitly citing electronic-materials expansion and R&D funding needs (FY2025 AR summary).

Products & Services

The company reports more than 200 product grades at scale (FY2023 AR). The catalogue below follows the product families in its filings and its English product taxonomy as summarised by S&P: polyolefin clarifiers, high-performance nucleators, β-nucleators, PA nucleators, PVC and polyolefin acid scavengers, Non-Dust One-pack (NDO), preblends, masterbatches, HALS/UVA light stabilisers and anti-block agents.

Nucleating agents (FY2025 revenue CNY 595.8M; GM 55.6%)

Product lineFunction / key specification (company disclosures)Target applicationStatus
Transparent nucleators (clarifiers)Haze reduced by more than 60%; heat-deflection and crystallisation temperature +5–10 °C; flexural modulus +10–15%; shorter cycle timeHigh-melt-flow PP; clear PP cups, food containers, infant bottles, medical syringesMature; capacity reallocated toward clarifiers in 2024 because of higher value-add
Stiffening nucleatorsFlexural modulus and strength +20% or more; HDT +15–25 °C; warpage controlThin-wall automotive PP, high-stiffness/high-toughness PP, packagingMature. Some stiffening-agent equipment was idle in 2025 because demand fell short of plan (Inquiry Reply).
β-crystal toughening nucleatorsβ-form conversion above 80%; impact strength up more than 3×. Tetrahydrophthalic-anhydride metal salt grade claimed as an industry first and registered as a new chemical substance in China.Impact PP, pipes, β-PPMature; niche
Calcium carboxylate stiffening nucleatorStiffening plus transparency and thermal stability for high-speed thin-wall injection mouldingThin-wall packaging (delivery and express logistics)Launched about 2022 as an import substitute
PA (nylon) nucleatorsCrystallisation control in polyamideEngineering plasticsListed in product range; details not disclosed
4th-generation organophosphate nucleatorBenchmarked against Milliken's Millad seriesHigh-end clear PPUnder customer validation as of Sep 2026 investor Q&A; timetable not disclosed
Nucleator compound additivesCustomised one-pack blends containing GCH nucleatorsPetrochemical resin gradesMature

Pricing (FY2025, Inquiry Reply). Average selling price was CNY 51,300/t (FY2024: CNY 52,500/t). Average unit cost was CNY 22,800/t (FY2024: CNY 23,200/t).

Synthetic hydrotalcite (FY2025 revenue CNY 126.2M; GM 44.6%)

Product lineComposition / functionApplicationNotes
General-purpose hydrotalciteMg-Al. PVC heat stabiliser; polyolefin acid scavenger with 4–6× the acid-absorption capacity of calcium stearatePVC pipes, profiles, cables; PP/PE polymerisationSupplied at scale to Adeka and Baerlocher (heat-stabiliser makers). The only domestic hydrotalcite specified by Sinopec besides imports.
High-transparency ternary hydrotalciteMg-Al-Zn; transparency 30–50% higher than general gradesTransparent PVC, medical PVC, high-end PP filmReplacing Kyowa Chemical and Sakai Chemical imports; extended into coatings in 2025
Flame-retardant hydrotalciteHalogen-free, low-smoke, non-corrosive; guanidine sulfamate and phytate intercalated gradesHalogen-free flame-retardant cableOne Chinese invention patent granted in 2023
Agricultural-film hydrotalciteEDTMP-intercalated; IR absorption at 7–25 µm, above 65% absorption at 9–11 µmGreenhouse filmOne Chinese invention patent granted in 2023
CO2-route hydrotalcite (process)Made from Al(OH)3, Mg(OH)2/MgO and CO2; no by-product salt and no wastewaterAll gradesGreen-process technology disclosed in FY2022 AR

Pricing (FY2025). Average selling price CNY 17,700/t (FY2024: CNY 16,600/t). Unit cost CNY 9,800/t (FY2024: CNY 8,800/t).

Antioxidants (FY2025 revenue CNY 114.0M; GM 11.6%)

Product lineFunctionApplicationNotes
Specialty hindered-phenol antioxidantsPrimary radical-scavenging anti-ageingNylon, polyolefins, wire and cable, rubber elastomers, polyether-polyurethaneFrom the Keao Chemical acquisition (2023). Customers include Sinopec, CNOOC, Adeka and SI Group (FY2023 AR).
Custom antioxidant blendsFormulated packagesSamePurification step added in 2025 for high-end grades

Pricing (FY2025). Average selling price CNY 23,200/t, up from CNY 16,000/t; unit cost CNY 20,500/t, up from CNY 13,600/t.

Compound additives, including NDO (FY2025 NDO revenue CNY 59.9M; GM 23.6%)

Product lineDescriptionTarget customer
NDO (Non-Dust One-pack)Granular, dust-free, all-in-one additive packages containing no GCH-made nucleator or hydrotalciteSinopec, PetroChina, CNOOC-Shell and others
Preblends and masterbatchesAdditive premixes and resin masterbatchesCompounders
HALS and UVA light stabilisers; anti-block and slip agentsPartly traded or blendedFilm and packaging producers

The company reports supplying more than 100 compound formulations to Sinopec, PetroChina, CNOOC-Shell, Yanchang Petroleum, Wanhua Chemical, Hengli Petrochemical, HMC (Thailand) and Formosa. NDO capacity utilisation was only 22.7% in FY2025. Production is deliberately intermittent because NDO is a commoditised, price-competitive line (Inquiry Reply).

Pricing (FY2025). Average selling price CNY 25,700/t, down from CNY 34,900/t because of customer mix.

Electronic materials (new in FY2026)

ProductFunctionStatus
Electronic-grade PPO (polyphenylene ether) resinLow-dielectric (low Dk/Df) matrix resin for high-frequency/high-speed CCLIn stable supply to CCL customers via Juxun (Guosen, Jun 2026). Planned Dongguan capacity: 2,500 t/yr.
High-frequency/high-speed halogen-free flame retardantsFlame retardancy for M6-and-above CCL with high purity and dielectric performanceSupplied to CCL customers. Planned Dongguan capacity: 2,500 t/yr.

Juxun reported FY2025 revenue of CNY 26.57M and a net loss of CNY 6.15M.

Trading products (FY2025 revenue CNY 81.4M)

CategoryModelNotes
General-purpose antioxidants, slip/anti-block agents, compound and premix additivesProprietary (gross)Declined in FY2025 on weaker demand
Catalysts (new in 2025), polypropylene, polyethylene, styrene-isoprene polymers, PTAAgency (net)Main customers are traders serving Middle East and domestic petrochemical plants

Pricing model (all lines). Negotiated contract pricing, bids and tenders for petrochemical customers, with consignment stock for some majors. List prices are not disclosed.

Financial Narrative

Basis. The tables below use S&P Global Market Intelligence standardised data (StockAnalysis.com, updated 20 Aug 2026), cross-checked against company filings on CFi.cn and annual-report summaries.

Known differences between S&P and company data:

  • FY2023 revenue in S&P is pre-restatement (CNY 799.63M); the company-restated figure is CNY 788.90M.

  • S&P "operating income" excludes interest income and investment income. The PRC-GAAP "operating profit" is higher: CNY 329.3M in FY2025 and CNY 291.7M in FY2024.

  • Per-share data are adjusted for the 1.4× capitalisation issue of June 2026.

Income statement

Notes on non-recurring net income. FY2021 is from the FY2021 AR. FY2024 and FY2025 are from CFi.cn.

EPS as originally reported (pre-adjustment, CNY): FY2021 1.35; FY2025 1.49. Guosen reports pre-bonus EPS of CNY 1.85 for FY2024 and CNY 1.46 for FY2025 on the post-bonus share base.

DPS conventions. S&P assigns dividends to the year in which they are paid or declared. Company-declared cash returns by fiscal year:

  • FY2021: CNY 50.00M (31.84% payout).

  • FY2022: no dividend, deferred because of the 2023 private placement.

  • FY2023: CNY 81.20M interim plus CNY 99.36M final plus CNY 23.82M buyback, totalling CNY 204.38M (90.38% of net profit).

  • FY2025: CNY 42.66M interim only (15.5% payout), plus a 4-for-10 capitalisation issue.

CAGR, FY2021–FY2025: revenue 14.1%; net income 15.1%; EBITDA 15.3%. FY2019–FY2021 revenue grew from CNY 392.1M to CNY 576.2M, a 21.2% CAGR (FY2021 AR).

Commentary.

Deceleration: Revenue growth slowed from 25% in FY2021 to about 9–12% in FY2024–FY2025. Net margin stayed between 27% and 29% throughout.

Gross margin trough and recovery: The FY2022 gross-margin trough of 41.9% reflects raw-material inflation and a heavier trading mix. The FY2025 peak of 45.0% reflects a smaller, more agency-weighted trading business and higher utilisation of the new Nansha capacity.

Treasury income: Pre-tax income runs about 3–5 points of revenue above EBIT because of the treasury book: interest income of CNY 43.3M plus investment income of CNY 17.7M in FY2025. This is large relative to a company of this size.

Earnings quality: Recurring net profit is about 95% of reported profit (FY2025: CNY 263.8M of CNY 275.8M).

Interim results — H1 2026 and quarterly run-rate

Source: 2026 half-year report summary, 21 Aug 2026. H1 2025 figures are restated.

How the quarterly figures are derived:

  • Q3 2025: nine-month CNY 227.79M less H1 CNY 147.25M.

  • Q4 2025: full year less nine months.

  • Q2 2026: H1 less Q1. Q1 2026 from the Q1 report.

  • Q3 2025 revenue uses restated nine-month revenue.

The H1 2026 profit decline has four identified drivers:

  • Selling expense rose 54.7% to CNY 25.6M, reflecting the Palmarole distribution consolidation and overseas expansion.

  • Management expense rose to CNY 39.9M, with 2026 share-incentive amortisation starting in Q2.

  • Foreign-exchange losses (S&P TTM shows CNY −14.8M).

  • Juxun losses.

Non-recurring gains, mainly fair-value gains of CNY 15.6M, provided 17.7% of H1 net profit. Recurring profit fell 22.4%.

Q2 2026 net profit of CNY 38.5M was the weakest quarter since listing. The sharp swing from Q1's CNY 90.2M signals rising cost intensity, as electronic materials and overseas distribution are built out ahead of revenue.

Balance sheet

Interim balance sheet (30 Jun 2026): total assets CNY 3,513.7M; equity attributable CNY 1,643.9M (H1 2026 report). Goodwill rose to CNY 94.3M at 31 Mar 2026 after the Juxun acquisition (S&P).

Commentary — the "bill-financing" balance sheet. The jump in short-term debt from CNY 1.3M (FY2021) to CNY 1.5bn (FY2023) is not conventional borrowing. The SSE inquiry reply explains the mechanism:

  • Intra-group and trading-related bank-acceptance bills are discounted at 0.60–1.65%.

  • Because they carry recourse, they stay on the balance sheet as "short-term borrowings": CNY 853.9M of FY2025's CNY 854.0M.

  • In parallel, the group holds CNY 1.15bn of time deposits, large-denomination certificates and USD principal-protected zero-coupon notes yielding 1.65–6.28%.

  • Of these, CNY 592M is pledged against bill and letter-of-credit issuance.

Interest expense of CNY 17.3M against interest plus investment income of CNY 53.1M (excluding receipt trading) shows the carry is positive. Restricted assets totalled CNY 675.7M at end-2025.

Gross leverage optics therefore overstate risk. They do, however, create rollover dependence on bank credit lines. At 31 Mar 2026, short-term borrowings had risen again to CNY 973.3M.

Cash flow

Notes:

  • The company-restated FY2023 operating cash flow is CNY 163.69M (Inquiry Reply restatement table).

  • Buybacks are derived from the change in treasury stock: CNY −23.82M at FY2023 and CNY −100M at FY2024.

  • H1 2026 operating cash flow was CNY 163.4M.

Commentary. Free cash flow fell to CNY 44M in FY2023 because Nansha capex peaked and receivables and other working capital absorbed cash. It recovered to CNY 218M in FY2025 as capex normalised. Receivables are a growing watch-point:

  • Gross accounts receivable rose 31% in FY2025, against 12% revenue growth.

  • Receivables reached 30.2% of revenue in FY2025 (25.8% in FY2024; 20.0% in FY2023).

  • Post-period collection of FY2025 receivables reached only 86.1% by 31 May 2026, against 98.8% for FY2024 at the equivalent point.

Ratios

Sources and derivations:

  • ROE, ROA, ROIC, liquidity, leverage and turnover ratios are from S&P.

  • Interest coverage is derived as S&P EBIT divided by S&P interest expense.

  • DIO is derived as inventory divided by cost of revenue, times 365.

  • DSO uses company gross accounts receivable from the Inquiry Reply: FY2023 CNY 159.70M; FY2024 CNY 225.24M; FY2025 CNY 295.03M.

Cash conversion cycle. Not meaningful. Accounts payable in standardised data include notes payable of CNY 472.9M at FY2025, which reflect bill financing rather than trade credit. That distorts days payable outstanding.

Commentary.

ROE: ROE settled at about 19% after the IPO equity raise. Asset turnover is only about 0.3× because of the CNY 1–1.7bn treasury book. Operating ROIC on productive assets is substantially higher than reported ROA implies.

Liquidity: The current ratio below 1.0 in FY2022–FY2023 and FY2025 is an artefact of bill-financing classification. Long-dated deposits sit in non-current assets while the matching bills sit in current liabilities. Guosen and Lanjing News nonetheless flag liquidity as "tight-balanced".

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (CNY Mn)

Segment revenue (CNY Mn)FY2024FY2025

Nucleating agents

511.03595.76

Synthetic hydrotalcite

116.87126.18

NDO compound additives

57.7259.86

Antioxidants

70.63113.97

Trading business

115.6181.41

Total main business

871.86977.18

Segment YoY growth (%)

FY2025

—

Nucleating agents

16.58—

Synthetic hydrotalcite

7.97—

NDO compound additives

3.71—

Antioxidants

61.36—

Trading business

-29.58—

Segment share of revenue (%)

FY2024

FY2025

Nucleating agents

58.661.0

Synthetic hydrotalcite

13.412.9

NDO compound additives

6.66.1

Antioxidants

8.111.7

Trading business

13.38.3

Segment gross margin (%)

Segment gross margin (%)FY2024FY2025

Nucleating agents

55.9155.64

Synthetic hydrotalcite

47.0244.63

NDO compound additives

24.9223.62

Antioxidants

14.9311.60

Trading business

7.1430.23

Segment gross profit (CNY Mn, derived)

Segment gross profit (CNY Mn, derived)FY2024FY2025

Nucleating agents

285.7331.5

Synthetic hydrotalcite

55.056.3

NDO compound additives

14.414.1

Antioxidants

10.513.2

Trading business

8.324.6

Product revenue (CNY 100M)

Product revenue (CNY 100M)H1 2023

Nucleating agents

2.04

Synthetic hydrotalcite

0.48

Antioxidants

0.38

Compound additives

0.22

Trading goods

0.56

Channel revenue (CNY Mn)

Channel revenue (CNY Mn)FY2024FY2025

End customers (self-produced)

582.92651.26

Traders (self-produced)

173.34244.51

Group Entities

EntityRole

呈和科技股份有限公司 (parent)

Production (Baiyun), R&D, sales, trading

广州科呈新材料有限公司 Guangzhou Kecheng New Materials

Nansha production base (IPO project)

广州呈和塑料新材料有限公司 Guangzhou Chenghe Plastics New Materials

Trading and treasury; holder of time deposits

上海呈和国际贸易有限公司 Shanghai Chenghe International Trade

Trading

香港呈和科技有限公司 Hong Kong Chenghe Technology

Overseas sales hub; holds about CNY 550M of overseas cash and notes

天津信达丰进出口贸易有限公司 Tianjin Xindafeng Import & Export

Trading (acquired 2023)

广东呈和电子材料有限公司 Guangdong Chenghe Electronic Materials

Electronic-materials platform; Dongguan project owner

广东聚讯新材料有限公司 Guangdong Juxun New Materials (80.89%)

Electronic PPO resin and HF/HS flame retardants

PALMAROLE TRADING SAS (France, 100%)

European, Middle East and Americas distribution

中电科翌智航(重庆)科技有限公司 (48%, associate)

Drone and low-altitude-economy systems

Income statement (CNY Mn)

Income statement (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

576.22694.90799.63873.18977.42

Gross profit

254.74291.06348.08375.01439.91

SG&A

51.7162.1580.1290.1396.13

R&D expense

23.5528.6833.8035.3739.54

Operating income (EBIT, S&P basis)

172.64190.77233.43247.38289.72

EBITDA

181.96200.77250.32266.87322.14

Interest expense

1.2911.3625.0424.1717.31

Interest and investment income

5.9532.3752.4070.1160.98

Pre-tax income

181.79227.46263.27291.50323.46

Income tax

24.7632.2637.1441.2347.68

Net income attributable to parent

157.03195.20226.13250.27275.79

Net income excluding non-recurring items

147.40——234.96263.75

Per-share data (CNY, bonus-adjusted)

Per-share data (CNY, bonus-adjusted)FY2021FY2022FY2023FY2024FY2025

EPS basic

0.690.740.860.961.06

EPS diluted

0.690.740.860.961.06

Dividend per share

0.19100.6890.3060.164

Margins (%)

Margins (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

44.2141.8843.5342.9545.01

Operating margin (EBIT)

29.9627.4529.1928.3329.64

EBITDA margin

31.5828.8931.3030.5632.96

Pre-tax margin

31.5532.7332.9233.3833.09

Net margin

27.2528.0928.2828.6628.22

Effective tax rate

13.6214.1914.1114.1414.74

Growth (%)

Growth (%)FY2021FY2022FY2023FY2024FY2025

Revenue growth

25.1920.6015.079.2011.94

Net income growth

34.7524.3115.8510.6810.20

Income Statement and Margin Analysis (%)

H1 comparison (CNY Mn)H1 2025H1 2026

Revenue

467.51481.51

Total profit (pre-tax)

170.43143.53

Net income attributable

147.25128.73

Net income excluding non-recurring items

136.59105.94

Operating cash flow

106.86163.40

R&D (% of revenue)

4.594.78

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Quarterly revenue (CNY Mn)

Quarterly revenue (CNY Mn)Q3 2025Q4 2025Q1 2026Q2 2026

Revenue

266.47237.44249.18232.33

Quarterly net income attributable (CNY Mn)

Quarterly net income attributable (CNY Mn)Q3 2025Q4 2025Q1 2026Q2 2026

Net income

80.5448.0090.1938.54

Balance Sheet and Per-Share Data

Balance sheet (CNY Mn, year-end)FY2021FY2022FY2023FY2024FY2025

Total assets

1,1612,3903,3113,2883,068

Cash and equivalents

306.95267.85637.94466.93659.84

Cash and short-term investments

538.02383.421,1371,690971.32

Long-term investments (deposits, notes, fund, equities)

160.621,3651,395604.63960.99

Accounts receivable (S&P incl. notes)

180.09270.89249.66327.48397.47

Inventory

50.1062.9870.8772.8588.35

PP&E

124.86177.48297.02408.77401.74

Goodwill

0019.3619.3619.36

Other intangibles

42.6641.2946.8345.0543.30

Short-term debt

1.34868.111,5091,393854

Long-term debt (incl. lease liabilities)

12.728.883.9712.938.49

Total debt

14.06876.991,5131,405862.49

Net cash (positive) / net debt (negative), S&P

523.96-493.57-375.46284.46108.82

Total liabilities

251.811,3332,0341,9281,563

Shareholders' equity

908.801,0571,2771,3611,505

Working capital

548.34-562.07-477.67313.24-14.15

Book value per share (CNY, adjusted)

3.484.044.845.245.80

Cash flow (CNY Mn)

Cash flow (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Operating cash flow

289.92296.35159.06212.52284.29

Capital expenditure

69.3375.63114.94110.6666.37

Free cash flow

220.59220.7244.12101.86217.92

Share buybacks

0023.8276.180

FCF margin (%)

38.2831.765.5211.6722.30

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatiosFY2021FY2022FY2023FY2024FY2025

ROE (%)

25.8219.8619.3818.9819.25

ROA (%)

13.756.725.124.695.70

ROIC (%)

44.2416.9212.5215.5719.98

Current ratio (x)

3.270.580.761.170.99

Quick ratio (x)

2.990.500.691.070.90

Debt / equity (x)

0.020.831.191.030.57

Net debt / EBITDA (x)

-2.882.461.50-1.07-0.34

Interest coverage, EBIT / interest (x)

133.816.89.310.216.7

Asset turnover (x)

0.730.390.280.270.31

Inventory turnover (x)

7.587.146.756.936.67

Days inventory outstanding

5757575360

Days sales outstanding (gross AR basis)

——7394110

Region revenue (CNY Mn)

Region revenue (CNY Mn)FY2024FY2025

Domestic (PRC)

699.81714.62

Overseas

172.05262.56

Region growth (%)

FY2025

—

Domestic (PRC)

2.1—

Overseas

52.61—

Region share (%)

FY2024

FY2025

Domestic (PRC)

80.373.1

Overseas

19.726.9

Region gross margin (%)

FY2024

FY2025

Overseas

49.6156.94

Operating Areas

AreaTrendDrivers

Overseas (all)

+52.6% in FY2025, with margin up 7.3 points

Nucleator cost advantage versus Milliken. China's 34% retaliatory tariff on US-origin goods (April 2025) raised costs for US nucleator imports into China and pushed buyers toward domestic suppliers, which helped domestic share. Overseas growth came from traders and international petrochemical qualification. The higher margin reflects the clarifier mix abroad.

Domestic

+2.1% in FY2025

Petrochemical demand was steady, but the trading business fell 29.6% (largely domestic). Self-produced domestic sales grew faster than the headline.

Electronic materials (new)

From zero in FY2025 to consolidated Juxun revenue in FY2026

Revenue not separately disclosed for H1 2026

Year-end share price (CNY, bonus-adjusted)

Year-end share price (CNY, bonus-adjusted)FY2021FY2022FY2023FY2024FY2025

Close

26.7923.5419.1719.0629.43

Market Valuation

Market capitalisation (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Market cap

7,4846,5235,3085,0587,642

Valuation Multiples (x)

Valuation multiples (x)FY2021FY2022FY2023FY2024FY2025

P/E

47.6633.4223.4720.2127.71

EV/EBITDA

38.5332.7425.1521.0623.45

EV/Sales

12.179.467.876.447.73

P/B

8.246.174.163.725.08

Valuation Snapshot

MetricValue

Share price (CNY)

66.58

Market cap (CNY Bn)

17.29

Enterprise value (CNY Bn)

17.14

P/E TTM (x)

66.95

Forward P/E (x)

50.66

P/B (x)

10.48

EV/EBITDA TTM (x)

56.73

EV/Sales TTM (x)

17.29

P/FCF (x)

60.39

Dividend yield (%)

0.25

Beta

1.51

52-week range, adjusted (CNY)

22.06 – 99.94

Peer Valuation (X), Guosen 5 Jun 2026 Details

Peer valuation (x), Guosen 5 Jun 2026GCHShengquan Group

P/E FY2025

51.323.8

P/E FY2026E

40.833.2

P/E FY2027E

32.926.7

P/B FY2026E

12.44.1

Income Statement

Guosen forecasts (CNY Mn)FY2024FY2025FY2026EFY2027EFY2028E

Revenue

8829771,2221,5031,803

Net income attributable

250276347430522

Per-Share Data and Margin Analysis (%)

Guosen forecasts (per share and %)FY2024FY2025FY2026EFY2027EFY2028E

EPS (CNY, diluted on latest share count)

1.851.461.842.282.77

ROE (%)

18.418.320.622.724.2

EBIT margin (%)

27.830.031.431.431.4

Cash dividend declared (CNY Mn)

Cash dividend declared (CNY Mn)FY2021FY2022FY2023FY2025

Cash dividends

50.000180.5642.66

Buybacks counted as dividends

0023.820

Payout ratio (%)

Payout ratio (%)FY2021FY2022FY2023FY2025

Payout

31.84090.3815.5

Maturity Profile At 31 Dec 2025 Details

Maturity profile at 31 Dec 2025 (CNY Mn)Value

Short-term borrowings due within 12 months

853.99

Of which: discounted bills not derecognised

853.89

Long-term bank debt

0

Lease liabilities, current

5.04

Lease liabilities, non-current

3.45

Analyst Conclusions

Management guidance

No quantitative revenue or profit guidance has been published. Qualitative priorities are:

  • ramping Nansha utilisation;

  • overseas expansion via Palmarole;

  • commercialising PPO and HF/HS flame retardants;

  • completing Dongguan phase one (technical renovation done June 2026; greenfield build ongoing);

  • launching the 4th-generation clarifier.

Consensus expectations

The only verified forecast set is Guosen's (June 2026): FY2026E net income CNY 347M (+25.7%), FY2027E CNY 430M (+24.1%) and FY2028E CNY 522M (+21.3%).

The H1 2026 actual was CNY 128.7M, which implies H2 2026 must deliver about CNY 218M to meet the FY2026E. That would be a 70% step-up on H1 and roughly 2.6× the H2 2025 level of about CNY 128.5M. The FY2026 forecast is at material risk of downward revision.

Bull case

  1. Core franchise compounding plus operating leverage. Nucleator volumes grew 19% in FY2025 with flat 55% margins, and utilisation is only about 55%. Filling Nansha toward 80% would add earnings with minimal capex. Overseas sales grew 53% at a 57% margin, and Palmarole adds direct access to Borealis, BASF and Borouge.

  2. Electronic-materials optionality. PPO and HF/HS flame retardants serve a supply-tight AI-server CCL chain where domestic suppliers are few (Guosen). Planned capacity of 2,500 t of each could become a second growth engine. Electronic PPO typically commands higher unit values than polymer additives (directional; not quantified in sources).

  3. Balance-sheet and alignment support. Net cash is positive on the S&P definition (CNY 108.8M at FY2025), and the deposit book exceeds CNY 1bn. Insiders hold about 43% and bought CNY 60M of stock in August 2026. The new incentive plan ties 62 managers to performance.

Bear case

  1. Earnings momentum has rolled over while the multiple has tripled. H1 2026 recurring net profit fell 22.4%; Q2 2026 net profit was the lowest quarter since listing at CNY 38.5M. Meanwhile trailing P/E expanded from about 28× (end-2025) to about 67×.

  2. Capital-allocation and execution risk. The record of diversification is mixed: failed Yingri, loss-making Juxun, and drone and fund investments outside the core. Dongguan commits up to CNY 1.3bn, about 0.86× equity. Payout has been cut from 90% (FY2023) to 15.5% (FY2025).

  3. Earnings-quality and disclosure flags. Receivables are growing 2.5× faster than revenue, and post-period collections are slowing. Bill-financing gross-up adds complexity, three periods were restated, and an SSE inquiry letter followed. The petrochemical customer base is under margin stress.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
Late Oct 2026Q3 2026 reportWhether Q3 net profit recovers above about CNY 70M; selling- and management-expense run-rate; FX
Q4 2026Electronic-materials disclosureFirst segment revenue for PPO and flame retardants; named CCL customer qualifications (M6/M7 grades)
Q4 2026 – 2027Dongguan financingBank-loan versus equity issuance (dilution risk)
Ongoing4th-generation clarifierCustomer approvals versus Milliken Millad
OngoingReceivables and cash conversionDSO trend (110 days at FY2025); collection of the CNY 41M FY2025 balance outstanding at 31 May 2026
H1 2027FY2026 AR (about Apr 2027)Dividend policy reset; utilisation; Palmarole contribution; goodwill testing (Juxun)
2,027Incentive-plan vesting conditionsPerformance hurdles
MacroUS–China trade measures; PP and PVC marginsExport-channel risk; customer payment behaviour

Concluding analyst verdict

GCH Technology is a high-quality, small-cap specialty chemicals franchise that is now being priced as an electronic-materials growth platform before it has proven it can be one.

The core business is genuinely advantaged. Over five years the company has compounded revenue at 14% and net income at 15%, while holding net margins near 28% and earning about 19% ROE on an equity base inflated by cash. Its nucleating agents earn 55%+ gross margins against peers in the 25–31% range. It is the domestic champion in a market where imports still hold about two-thirds share. Overseas expansion at 57% margins and the Palmarole channel provide a credible runway that does not depend on any new technology.

The 2026 pivot changes the debate. The Juxun acquisition and the CNY 1.3bn Dongguan programme give real exposure to a supply-tight, AI-linked CCL materials chain. The market has capitalised that option generously: the shares are up about 2.3× year to date, at about 67× trailing earnings and over 10× book. Fundamental momentum, by contrast, has weakened:

  • H1 2026 recurring profit fell 22%;

  • Q2 2026 profit was a five-year low;

  • receivables are stretching;

  • capital is being redirected from dividends to an unproven segment, under an SSE inquiry spotlight.

On the evidence, the core business supports a premium specialty-chemicals valuation, and management's personal buying signals conviction. The current price, however, embeds successful electronic-materials execution that will not be visible in reported numbers until 2027 at the earliest. Guosen's FY2026 profit estimate appears too high given H1 delivery.

Our stance is constructive on franchise quality but cautious on valuation and near-term estimates. The decisive monitorables are disclosed PPO and flame-retardant revenue with named CCL qualifications, a Q3–Q4 2026 profit recovery, and receivables normalisation. Without them, the risk/reward skews to de-rating toward a core-business multiple, which historically sat at about 20–28× earnings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleBorn / ageTenure and backgroundEducationShareholding

Tong Jiaqi (仝佳奇)

Chairman; 4th-board nominee

Jul 1962 / 64

Director since 2008; GM 2008–Jun 2024; chairman since Sep 2023. Previously at MOFTEC (Ministry of Foreign Trade, 1986–94), Sinochem (1994–97), Vice President at First Pacific Bank Hong Kong (1997–99), then Sinochem International (office head, plastics division GM, GM of Sinochem HK Chemical and Sinochem Plastics, 1999–2007). Executive director of Shanghai Kehui since 2007.

BA in World Economics; MBA

Indirect 12.01M shares (4.63%) via a 47% stake in Shanghai Kehui

Zhao Wenlin (赵文林)

Founder, Honorary Chairman, director, chief engineer; controlling shareholder; 4th-board nominee

Oct 1964 / 61

Founded the company in 2002; chairman 2002–Sep 2023. Previously technician at Guangzhou Huali Pigment Chemical (1988–92); deputy GM then GM at Guangzhou Yuanfeng Plastic Additives (1992–2002).

Chemical-engineering bachelor's; professor-level senior engineer

100.03M shares (38.52%) direct plus via Zhongcheng

Zhao Wensheng (赵文声)

Director since Sep 2021; nominee

Sep 1970 / 56

Highway-engineering career: deputy GM at Guangdong Changda Highway Engineering; head of the Guangdong Highway Quality Monitoring Centre; head of Guangdong Road & Bridge Planning Research Centre; Beijing Xinqiao Technology. Brother of Zhao Wenlin.

PhD; senior economist

19,600 shares

Zhao Wenhao (赵文浩)

Director since Mar 2016; nominee

Feb 1973 / 53

Engineering and equipment roles at the predecessor company (2004–16). Brother of Zhao Wenlin.

BA in Enterprise Management

29,400 shares (indirect)

Que Zhanwen (阙占文)

Independent director since Sep 2023; nominee

Feb 1979 / 47

Law professor and PhD supervisor at Sun Yat-sen University; part-time lawyer; arbitrator

PhD

—

Huang Guangming (黄光明)

Independent-director nominee (accounting expert)

Nov 1970 / 55

Former CFO of Anjubao Digital and Gaolan Energy-Saving; current CFO of Guangzhou Chuangtian Electronic; independent director at Shenzhen Guanghua Weiye and Jiangsu Taimushi

BA in Accounting; senior accountant

—

Liang Wenfei (梁文飞)

Independent-director nominee

May 1990 / 36

Polymer and drug-delivery R&D roles (Baiyunshan Pharma; Dazhou Biomed; Kunshan Xinyunda)

BSc and MSc, Peking University

—

Executive Leadership Team

NameTitleNotes

Zhang Xu (张旭)

General Manager (CEO)

He succeeded Tong Jiaqi as GM after June 2024. Participated in the 2026 management share purchase.

Yu Zhiliang (余志亮)

CFO

Previously head of the accounting function (Q1 2024 filings)

Duan Shuli (段淑丽)

Investment Director

Participated in the 2026 share purchase

Hu Zhiyi (胡志毅)

Board Secretary

Succeeded Yang Yanfang (Board Secretary in 2022)

Chen Yinghong (陈映红)

Core employee; formerly head of accounting (2022–23)

Participated in the 2026 share purchase

Board & Management Changes

DateChange

Sep 2023

Zhao Wenlin moves from chairman to Honorary Chairman; Tong Jiaqi becomes chairman (also GM)

Jun 2024

Tong Jiaqi relinquishes the GM role; Zhang Xu becomes GM

Jul 2024

Core technical staff member Wei Yongquan departs

1 Jun 2026

By-election of an independent director

20 Aug 2026

4th-board slate nominated: incumbents re-nominated; two new independents (Huang, Liang)

7 Sep 2026

EGM to elect the 4th board.

Major Shareholders

HolderTypeStake (%)Shares

Zhao Wenlin

Individual (controlling shareholder)

34.3890,258,000

Ru Fei (茹菲)

Individual; acts in concert with Shanghai Kehui

13.0734,300,000

Shanghai Kehui Investment Management

Corporate (Tong Jiaqi holds 47%)

9.7425,561,476

Cui Hao (崔皓)

Individual

3.8310,058,277

Guangzhou Zhongcheng Investment LP

Employee/founder vehicle; acts in concert with Zhao

3.739,800,000

Cai Jiayu

Individual

1.223,214,400

Kuang Xiaoye

Individual

1.072,806,361

He Jiayi

Individual

0.772,027,990

Fullgoal Tianyi Value Hybrid Fund (Bank of Communications)

Mutual fund

0.751,962,500

Wang Manli

Individual

0.711,874,628

Competitive Landscape

Competitors by Segment

SegmentCompetitorOrigin / listingPositioning relative to GCH

Nucleators and clarifiers

Milliken & Company (Millad, Hyperform)

US; private

Global technology and share leader in sorbitol clarifiers. GCH positions its products as comparable in performance and cheaper (Guosen, Apr 2025).

Nucleators

ADEKA Corporation (ADK STAB NA series)

Japan; TSE 4401

Phosphate-ester nucleator leader. Also a GCH customer for hydrotalcite and antioxidants (co-opetition).

Nucleators

New Japan Chemical (Rikaclear / Gel All)

Japan; TSE 4406

Sorbitol clarifier competitor

Nucleators / additives

BASF (Irgaclear, Irganox)

Germany; XETRA BAS

Broad additive portfolio; global scale

Synthetic hydrotalcite

Kyowa Chemical Industry

Japan; private

High-end hydrotalcite leader (imports into China)

Synthetic hydrotalcite

Sakai Chemical Industry

Japan; TSE 4078

High-end PVC and PP hydrotalcite

Synthetic hydrotalcite / additives

Clariant

Switzerland; SIX CLN

Named by Guosen as a high-end hydrotalcite incumbent

Antioxidants

Songwon Industrial

Korea; KRX 004430

Global #2 polymer stabiliser maker

Antioxidants / light stabilisers

Rianlon (利安隆)

China; SZSE 300596

Domestic stabiliser leader with far larger antioxidant scale

Electronic PPO resin

SABIC; Mitsubishi Gas Chemical; Asahi Kasei

Saudi Arabia; Japan (TSE 4182, TSE 3407)

Global PPO capacity is concentrated here (Guosen)

Electronic PPO resin

Shengquan Group (圣泉集团)

China; SSE 605589

Domestic leader in electronic resins; market cap about CNY 44.6bn (Jun 2026)

Electronic PPO resin

Dongcai Technology (东材科技)

China; SSE 601208

Domestic electronic-resin producer

HF/HS flame retardants

Jinyi Chemical (晋一化工)

Taiwan

Current main supplier for M6-and-above CCL flame retardants (Guosen)

Polymer additives (company-chosen comparables)

Tongcheng New Materials (彤程新材); Yoke Technology (雅克科技); Huicheng Environmental (惠城环保)

China A-shares

Used by GCH in its own margin benchmarking

Competitor Detail

Gross margin (%)FY2024FY2025

GCH Technology

43.5345.02

Tongcheng New Materials

24.8424.20

Yoke Technology

31.5930.96

Huicheng Environmental

24.7429.17

Peer average

27.0628.11

Competitor Detail — GCH Technology

Inventory write-down ratio, end-2025 (%)Value

GCH Technology

0.11

Tongcheng New Materials

1.73

Yoke Technology

2.65

Huicheng Environmental

0.02

Valuation versus closest electronic-resin peer (Guosen, 5 Jun 2026)

GCH

Market cap (CNY 100M)

197

EPS FY2025 (CNY)

1.46

EPS FY2026E (CNY)

1.84

P/E FY2026E (x)

40.8

P/B FY2026E (x)

12.4

Recent Developments

--

Company Snapshot

$135.9M

Revenue

255

Employees

$2,400M

Market Cap

2002

Founded

SWOT Analysis

Strengths

  • Pricing power in the core. Nucleator gross margin was 55.64% in FY2025 versus 55.91% in FY2024, despite a 2.3% price cut (Inquiry Reply).
  • Structural margin premium over peers. Group gross margin of 45.0% compares with a 28.1% peer average in FY2025 (company benchmark).
  • Blue-chip, sticky customer base. Customers include Sinopec, PetroChina, CNOOC-Shell, Wanhua and Hengli. GCH is the only domestic hydrotalcite designated by Sinopec alongside imports (FY2021–FY2023 ARs).
  • Consistent profitability. Net margin stayed between 27.3% and 28.7% across FY2021–FY2025. Net income CAGR was 15.1% (S&P).
  • Strong cash generation. FY2025 operating cash flow of CNY 284M was 103% of net income; FY2025 free cash flow was CNY 218M (S&P).
  • Aligned, founder-led ownership. Insiders hold about 43%, and management bought CNY 59.9M of shares in August 2026.
  • Credentials. FDA food-contact clearance, Novolen/Unipol qualifications, and National Single-Item Champion status for nucleators.

Weaknesses

  • Under-utilised assets. Nucleator and hydrotalcite utilisation was 55–57%, NDO 22.7%; CNY 4.78M of equipment was idle in 2025 (Inquiry Reply).
  • Customer concentration. Top-5 customers were 35.7% of revenue and the largest 13.4% (FY2025).
  • Rising receivables. Accounts receivable reached 30.2% of revenue, up from 20.0% in FY2023. FY2025 post-period collection was 86.1%, against 98.8% for FY2024 (Inquiry Reply).
  • Opaque, bill-financed balance sheet. CNY 854M of short-term borrowings sits alongside CNY 1.73bn of cash and deposit-type assets, with CNY 676M of restricted assets. The arrangement attracted an SSE inquiry.
  • Low-margin adjacencies. Antioxidant gross margin is 11.6% and NDO 23.6%. Together they are 17.8% of revenue but only 6.2% of gross profit.
  • Limited institutional following. Only one fund appears in the top 10 holders, and S&P records no consensus price target.
  • R&D asset base is old. R&D equipment newness ratio is 15.3%.

Opportunities

  • Nucleator import substitution. Domestic share is about 30%, against a projected 34% in 2025. Tariffs on US goods raise the cost of Milliken imports (Guosen, Apr 2025).
  • Overseas expansion. Overseas revenue grew 52.6% in FY2025 at a 56.9% margin. Palmarole adds Borealis, BASF and Borouge access.
  • High-end hydrotalcite. The Dongguan project adds 20,000 t/yr of high-end hydrotalcite, targeting Kyowa, Sakai and Clariant's segments.
  • Electronic materials. PPO and HF/HS flame retardants for AI-server CCL are supply-tight (Guosen). 2,500 t of each is planned.
  • 4th-generation clarifier. Matching Milliken Millad would open the premium clear-PP tier.
  • Operating leverage. Raising utilisation from 55% toward 80% on existing capacity requires little additional capex.

Threats

  • Earnings momentum broke in 2026. H1 2026 recurring net profit fell 22.4%, and Q2 2026 net profit was CNY 38.5M against CNY 90.2M in Q1.
  • Execution risk on a CNY 1.3bn project. The Dongguan commitment is about 0.86× FY2025 equity, and the acquired electronic-materials base is loss-making (Juxun: FY2025 net loss of CNY 6.2M).
  • Entrenched electronic-resin competitors. SABIC, Mitsubishi Gas Chemical, Asahi Kasei, Shengquan and Dongcai; Guosen notes a domestic gap in high-purity, low-Dk grades.
  • Customer stress in petrochemicals. Juzhengyuan, a GCH partner and investee, lost CNY 549M in FY2025.
  • Regulatory scrutiny. The SSE inquiry letter (2026) and the restatement of three periods' revenue increase disclosure risk.
  • Valuation risk. Trailing P/E of about 67× and P/B of about 10.5× (S&P, 30 Sep 2026) leave little room for delivery shortfalls.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
9 Apr 2025Letter of intent to acquire at least 51% of Yingri Technology (CNY 1.8bn valuation)First attempt at diversification into electronics
10 Apr 2025China's 34% retaliatory tariff on US goods takes effect; Guosen flags nucleator import-substitution acceleration versus MillikenPositive for domestic share
29–30 Apr 2025FY2024 AR and Q1 2025: FY2024 revenue CNY 882M (later restated to CNY 873M), net profit CNY 250M (+10.6%)Steady growth
20 May 2025FY2024 AGM; authorises board to set a 2025 interim dividendCapital return
Jun 2025Yingri acquisition terminatedStrategic setback
14–16 Aug 2025H1 2025 results (net profit CNY 147M); interim dividend of CNY 2.30 per 10 shares approvedOverseas growth highlighted by Guosen
Sep 2025Interim dividend of CNY 42.66M paidSmaller payout than FY2023
29 Oct 2025Q3 2025: nine-month net profit CNY 228MGuosen: "steady growth, overseas strong"
15 Dec 2025Board approves Palmarole (USD 24M total) and CETC Yizhihang (48%) dealsInternationalisation and diversification
30 Dec 2025Guangdong Commerce Department ODI certificate for PalmaroleRegulatory step
Jan 2026Acquires 80.89% of Juxun New MaterialsEntry into CCL electronic materials; stock re-rating catalyst
3 Feb 2026Guangdong NDRC approves Palmarole project changeRegulatory step
16 Mar 20262026 restricted-stock incentive plan proposedRetention
28–29 Apr 2026FY2025 AR: revenue CNY 977M (+11.9%), net profit CNY 276M (+10.2%); 4-for-10 bonus issue, no final cash dividend; prior periods restated for warehouse-receipt accounting. Q1 2026: revenue CNY 249M, net profit CNY 90M.Shift toward reinvestment
30 Apr 2026Guosen: "overseas breakthrough; entry into high-end electronic materials"Sell-side endorsement
20 May 2026FY2025 AGM approves bonus issue, treasury-share cancellation and incentive planCapital structure
21 May 2026Grants 4.8M restricted shares at CNY 30.00 to 62 granteesIncentive alignment
1 Jun 2026Board by-elects an independent directorGovernance
2 Jun 2026Announces up to CNY 1.3bn Dongguan HF/HS electronic-materials and high-end additives projectLargest capex commitment in company history (about 0.86× FY2025 equity)
4 Jun 2026Bonus issue completed (262.51M shares)Liquidity
8 Jun 2026Guosen maintains "Outperform"; FY2026–FY2028E net profit CNY 347M / 430M / 522MConsensus anchor
9 Jun 2026Joins UN Global CompactESG signalling
23 Jun 2026Management share-purchase plan (CNY 30–60M)Insider confidence
8 Jul 2026Reply to SSE inquiry letter on FY2025 AR covering capacity utilisation, trading business, cash-and-debt coexistence, receivables, inventory and investmentsRegulatory scrutiny of earnings quality and treasury
20–21 Aug 2026H1 2026: revenue +3.0%, net profit −12.6%, recurring profit −22.4%; selling expense +54.7%; Dongguan phase-one technical renovation essentially complete by end-JuneEarnings momentum weakens
20 Aug 20264th-board nominations; incentive price and quantity adjusted to CNY 21.43 and 6.72M sharesGovernance continuity
Aug 2026Management share purchase completed (CNY 59.92M)Insider buying near the H1 print
7 Sep 2026EGM on board renewal–
16 Sep 2026Investor Q&A: 28 R&D projects; 4th-generation clarifier in validation versus Milliken MilladProduct pipeline
30 Sep 2026Shares close at CNY 66.58 (market cap about CNY 17.3bn), roughly 2.3× the end-2025 levelValuation now discounts the electronic-materials optionality

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from CNY 576.2 Mn in FY2021 to CNY 977.4 Mn in FY2025.
GCH Technology Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue576.2694.9799.6873.2977.4
Gross profit254.7291.1348.1375439.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. GCH Technology — Reply to SSE Inquiry Letter on 2025 Annual Report (Ann. 2026-035), 8 Jul 2026 (pdf.dfcfw.com)
  2. GCH Technology — 2026 Half-Year Report Summary; Board Resolution 2026-046; Board Renewal 2026-045; EGM Notice 2026-047; Incentive Adjustment 2026-044 (China Securities Journal, 21 Aug 2026) (epaper.cs.com.cn)
  3. GCH Technology — 2025 Annual Report Summary (China Securities Journal, 30 Apr 2026) (epaper.cs.com.cn)
  4. GCH Technology — 2023 Annual Report Summary and Q1 2024 Report (Shanghai Securities News, 23 Apr 2024) (paper.cnstock.com)
  5. GCH Technology — 2022 Annual Report Summary (Shanghai Securities News, 25 Apr 2023) (paper.cnstock.com)
  6. GCH Technology — 2021 Annual Report Summary and Q1 2022 Report (China Securities Journal, 27 Apr 2022) (epaper.cs.com.cn)
  7. GCH Technology — 2021 Profit Distribution and Fund-Use Announcements (China Securities Journal, 27 Apr 2022) (epaper.cs.com.cn)
  8. GCH Technology — Treasury-Share Cancellation Notice (Ann. 2026-023) (paper.cnstock.com)
  9. GCH Technology — Board Resolutions 2026-025 and 2026-029 · paper.cnstock.com
  10. GCH Technology — Yingri restructuring announcements (2025-010, 2025-026) · paper.cnstock.com
  11. GCH Technology — Core Technical Staff Change (2024-027) (paper.cnstock.com)
  12. GCH Technology — Management Share Purchase Completion (Aug 2026) (pdf.dfcfw.com)
  13. Guosen Securities — "From resin-additive leader to HF/HS electronic-materials platform", 8 Jun 2026 (pdf.dfcfw.com)
  14. Eastmoney research summary of the Guosen report (data.eastmoney.com)
  15. Caiwen News — Dongguan project announcements, 2 Jun 2026 (caiwennews.com)
  16. Lanjing News — H1 2026 results analysis, 20 Aug 2026 (lanjinger.com)
  17. Stockstar / Huaxi Securities — H1 2023 review (stock.stockstar.com)
  18. Fxbaogao / Guosen — April 2025 report summary (fxbaogao.com)
  19. Stockstar — investor Q&A, Sep 2026 (wap.stockstar.com)
  20. StockAnalysis.com (S&P Global Market Intelligence data) — overview, financials, income statement, balance sheet, ratios (stockanalysis.com)
  21. CFi.cn — income statement and financial indicators · quote.cfi.cn
  22. Morningstar Australia — company profile (morningstar.com.au)
  23. Simply Wall St — company profile (simplywall.st)
  24. Moomoo — company profile (moomooapp.com)
  25. UN Global Compact participant page (unglobalcompact.org)
  26. PEdaily — IPO approval coverage, 2021 (news.pedaily.cn)
  27. Financialfilings.com (description conflict noted) (financialfilings.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.